Here's Why Novavax Stock Is Moving

Novavax, Inc. NVAX shares are trading higher in sympathy with Moderna Inc MRNA, which reported better-than-expected second-quarter results.

Quarterly revenue for Moderna was $4.75 billion compared to $4.34 million a year ago, beating the consensus of $4.07 billion.

Moderna has authorized an additional share repurchase program for $3 billion. The $3 billion repurchase program announced in February is continuing and currently has approximately $1 billion outstanding… Read More

See Also: Why Kintara Therapeutics Stock Is Skyrocketing Today

According to data from Benzinga Pro, Novavax has a 52-week high of $277.80 and a 52-week low of $34.88.

Image and article originally from Read the original article here.